Allarity Therapeutics, Inc. has announced a significant restructuring of its debt through an Exchange Agreement with Streeterville Capital, LLC. This agreement, made on November 12, 2026, allows the company to partition a portion of its existing debt into a new promissory note and issue Series B Preferred Stock in exchange. This strategic move aims to enhance Allarity's financial stability as it continues to develop its pharmaceutical offerings.
Allarity Therapeutics, based in Boston, operates in the pharmaceutical preparations sector, focusing on innovative treatments for cancer. The company trades on the Nasdaq under the ticker symbol ALLR. This recent filing marks a notable event in Allarity's ongoing financial strategy, as it seeks to optimize its capital structure and support its research and development efforts.
According to the filing, the Exchange Agreement involves the partitioning of a $10,930,000 promissory note into a new $3,000,000 note, which will be exchanged for 3,000 shares of Series B Preferred Stock. The outstanding balance of the original note will be reduced by the same amount. The transaction was completed on November 16, 2026, following the filing of a Certificate of Designation with the Secretary of State of Delaware.
The newly issued Series B Preferred Stock will have a stated value of $1,050 per share and will accrue a preferred return of 9% per annum, payable quarterly. This stock ranks senior to Allarity's common stock concerning dividends and liquidation preferences. The issuance of this preferred stock may impact existing shareholders, as it introduces new rights and preferences that could affect the overall equity structure.
Additionally, the Exchange Agreement includes provisions that restrict Allarity from issuing further debt or equity securities without the consent of the Series B Preferred Stock holders. These restrictions aim to maintain the company's financial health and ensure that the interests of the new preferred shareholders are safeguarded.
In a related note, Allarity also announced an expansion of eligibility for its ongoing Phase 2 trial of stenoparib, a dual PARP and WNT pathway inhibitor for advanced ovarian cancer. This expansion includes patients with primary platinum-refractory disease, further emphasizing the company's commitment to advancing its clinical trials and drug development.
The implications of this Exchange Agreement are significant for Allarity and the broader pharmaceutical preparations industry. As Allarity navigates this restructuring, competitors will observe how these changes affect the company's operational capabilities and market position. The filing does not specify what will happen next, but the company's financial maneuvers will likely be closely monitored by investors and industry analysts alike.
Read Next
Klarna Group Reports Strong Q3 2026 Financial Results
Vodafone Group Amends Terms of Capital Securities in 6-K
SOS Ltd Announces $16 Million Share Sale Agreement
BBCMS Mortgage Trust 2026-5C43 Issues Commercial Mortgage Certificates
Purple Biotech Reports Q3 2026 Results, Updates on IM1240
CFO Kimble John Louis sells 67,459 shares of JAKKS Pacific








